Tejas Patil, MD, offers a preliminary overview of the latest developments in non-small cell lung cancer research from the ASCO conference. Pivotal studies such as the LAURA trial, which showcased the potential of early intervention with osimertinib in EGFR-mutant lung cancer post-chemoradiotherapy, underscore the need for a paradigm shift in treatment approaches. Similarly, the CROWN trial's comparison of lorlatinib to crizotinib in ALK-rearranged lung cancer not only revealed impressive intracranial control, but more generally prompts reconsideration of drug selection in this context.
With insights from studies like PALOMA-3, BLOSSOM, and NRG-LU002, Dr Patil outlines a landscape where advancements in therapy formulations and treatment strategies prompt critical reevaluation within the oncology community, fostering anticipation of vibrant discussions and potential shifts in clinical practice in the months ahead.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Tejas Patil. ASCO 2024: Practice-Changing Data for the Treatment of Advanced NSCLC - Medscape - Jun 10, 2024.
Comments